The fast development of vaccines in the face of the Covid-19 pandemic demonstrated the skills and expertise of the pharmaceutical industry.

However, the speedy response to this global crisis belies the fact that in many cases, the product development process for a new drug or treatment can be very lengthy and costly, with no guarantee that it will be approved for commercialization.

One of the stumbling blocks to obtaining approval is an inability to demonstrate a drug’s efficacy. This does not mean a drug is ineffective but could instead be the result of poor adherence preventing the drug from performing to its full potential.

The introduction of digital technology into standard plastic closures used in drug trials is a breakthrough that can enhance medicine adherence and provide valuable insights into its effectiveness directly relative to the prescribed regime.

Poor medication adherence has been recognized as a long-standing problem in clinical trials, as developers have historically relied on subjective measurements, including pill counting, self-reporting, or invasive techniques, such as tracking product levels in blood or urine.

Berry’s Digi-Cap™ makes it possible to measure and report relevant adherence data independently as part of a clinical trial, including the time the package was opened and important temperature information.

Download and read the complete Berry white paper:
How Digital Cap Technology Can Improve Medicine Adherence